Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.49 |
| ▸ | CDK2 | P24941 | 14/20 | 0.49 |
| ▸ | CCND1 | P24385 | 11/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532459 | 0.97 | MAPK14 (0.53) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3535627 | 0.90 | MAPK14 (0.48) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3534149 | 0.89 | MAPK14 (0.65) | MAPK14LCKMAPK8MAPK9MAPK10 | |
| SCHEMBL3541762 | 0.87 | MAPK14 (0.50) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3532738 | 0.86 | MAPK14 (0.49) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3535700 | 0.80 | MAPK14 (0.63) | MAPK14LCKMAPK8MAPK9MAPK10 | |
| SCHEMBL3537917 | 0.80 | MAPK14 (0.63) | MAPK14LCKMAPK8MAPK9MAPK10 | |
| SCHEMBL3677049 | 0.80 | MAPK14 (0.64) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3535335 | 0.79 | MAPK14 (0.61) | MAPK14LCKMAPK8MAPK9MAPK10 | |
| SCHEMBL3536515 | 0.79 | MAPK14 (0.60) | MAPK14LCKMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | claimed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | MAP3K6, MAP3K1, MAP3K2 | MAPK14 44/4885CCNE1 691/4885CDK2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.